Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

11/12/24 4:47:45 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RGNX alert in real time by email

SC 13G/A 1 UnitedStates_13G__REGENXBIOI.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* (Name of Issuer) REGENXBIO Inc (Title of Class of Securities) Common Stock (CUSIP Number) 75901B107 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 75901B107 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 29,581 (7) Sole dispositive power 4,302,200 (8) Shared dispositive power 66,791 (9) Aggregate amount beneficially owned by each reporting person 4,368,991 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 8.83% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: REGENXBIO Inc Item 1(b) Address of issuer's principal executive offices: 9804 Medical Center Drive Rockville, MD 20850 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 75901B107 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 4,368,991 (b) Percent of class: 8.83% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 4,368,991 (b) Percent of class: 8.83% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 29,581 (iii) Sole power to dispose or to direct the disposition of: 4,302,200 (iv) Shared power to dispose or to direct the disposition of: 66,791 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

Get the next $RGNX alert in real time by email

Recent Analyst Ratings for

$RGNX

Date	Price Target	Rating	Analyst
11/15/2024	$22.00	Overweight	Morgan Stanley
10/10/2024	$18.00	Outperform	Raymond James
6/7/2024	$38.00	Buy	Goldman
3/11/2024	$36.00	Buy	H.C. Wainwright
3/8/2024	$20.00 → $35.00	Sector Perform → Outperform	RBC Capital Mkts
3/6/2024	$37.00	Market Perform → Outperform	Leerink Partners
2/21/2024	$45.00	Outperform	Raymond James
11/1/2023	$35.00	Buy	Stifel

More analyst ratings

Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

Chat with this insight

Recent Analyst Ratings for $RGNX

$RGNX Press Releases

Fastest customizable press release news feed in the world

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

$RGNX SEC Filings

SEC Form 10-Q filed by REGENXBIO Inc.

REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

REGENXBIO Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

$RGNX Financials

Live finance-specific insights

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

$RGNX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$RGNX Market Insights

Live Market Insights

$RGNX Leadership Updates

Live Leadership Updates

Director Karabelas Argeris N exercised 10,000 shares at a strike of $3.76 and sold $101,052 worth of shares (10,000 units at $10.11) (SEC Form 4)

Chief Financial Officer Chan Mitchell was granted 58,869 shares (SEC Form 4)

SEC Form 3 filed by new insider Chan Mitchell

Why Is Clearside Biomedical Stock Gaining Today?

REGENXBIO Expands Its AFFINITY DUCHENNE Trial To Include A New Cohort Of Younger Patients

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

REGENXBIO Announces Leadership Transition

Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors

$RGNX Large Ownership Changes

This live feed shows all institutional transactions in real time.